Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

clinical trial

Wikidata entity: Q99956427



Quantities

P4135maximum age75
P2899minimum age18
P1132number of participants53

P6099 clinical trial phase ... Q42824440 (phase II clinical trial) phase II clinical trial
P582 end time ... 2023-05-01 ???
P31 instance of ... Q30612 (clinical trial) clinical trial
P6153 research site ... Q11102507 (Hangzhou First People's Hospital) Hangzhou First People's Hospital
P8005 research subject recruitment status ... Q76649614 (not yet recruiting) not yet recruiting
P1813 short name Monolingualtext AUTUMN ???
P580 start time ... 2020-11-01 ???
P8363 study type ... Q78089383 (interventional study) interventional study
P1476 title Monolingualtext Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial ???

External Ids
P3098ClinicalTrials.gov IDNCT04553887

Why not click here or view trends?

log id: 4706530